Profiel
Ann-Sofie Sternås is currently working as the Director of Intellectual Property at Akinion Pharmaceuticals AB. Previously, she held positions as the Director of Intellectual Property at Axelar AB, Principal at AstraZeneca AB, and Vice President of Intellectual Property Rights at ClanoTech AB.
Actieve functies van Ann-Sofie Sternås
| Bedrijven | Functie | Begin |
|---|---|---|
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical for the treatment of acute myeloid leukemia | Corporate Officer/Principal | - |
Eerdere bekende functies van Ann-Sofie Sternås
| Bedrijven | Functie | Einde |
|---|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services Researches and develops pharmaceutical products | Corporate Officer/Principal | - |
Axelar AB
Axelar AB BiotechnologyHealth Technology Provides oral anti-cancer therapies | Corporate Officer/Principal | - |
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of cancer and macular degeneration | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services Researches and develops pharmaceutical products | Commercial Services |
Axelar AB
Axelar AB BiotechnologyHealth Technology Provides oral anti-cancer therapies | Health Technology |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical for the treatment of acute myeloid leukemia | Health Technology |
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of cancer and macular degeneration | Health Technology |
















